Oxybutynin Chloride
Product Images NDC 53808-1122

8 FDA label images from Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 53808-1122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 5mg (Oxybutynin Cl 5mg)

Label Image For 5mg (Oxybutynin Cl 5mg)
Label for Oxybutynin Chloride 5 mg tablets showing quantity of 30 tablets. The label includes manufacturing details with manufacturer KVK, packaging by DOH Central Pharmacy in Tallahassee, FL 32304, expiration date 07-10-19, and a barcode with UPC 310702201101. It is marked as prescription only (Rx Only).*
FDA Label Image

Structural Formula (Figure 1 Structure)

Structural Formula (Figure 1 Structure)
Chemical structure of oxybutynin hydrochloride, showing its molecular arrangement including a phenyl ring, cyclohexane ring, ester linkage, alkyne group, and diethylamino substituent with hydrochloride salt.*
FDA Label Image

Table 1 (Figure 2 Table1)

Table 1 (Figure 2 Table1)
A data table presenting pharmacokinetic parameters of R-Oxybutynin and S-Oxybutynin enantiomers, including Cmax (ng/mL), Tmax (hours), AUCt (ng·h/mL), and AUCinf (ng·h/mL), with mean values and standard deviations shown in parentheses.*
FDA Label Image

Figure 1 (Figure 3 Figure1)

Figure 1 (Figure 3 Figure1)
A line chart depicting the mean plasma concentrations of R-Oxybutynin over 24 hours with time in hours on the x-axis and concentration in ng/mL on the y-axis. Data points show plasma concentration levels following administration of Oxybutynin 5 mg TID, illustrating peaks and declines across the dosing period.*
FDA Label Image

Table 2 (Figure 4 Table2)

Table 2 (Figure 4 Table2)
A data table presenting pharmacokinetic parameters for R-oxybutynin, S-oxybutynin, R-desethyloxybutynin, and S-desethyloxybutynin, including maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the curve (AUC). Statistical values are provided as means with standard deviations.*
FDA Label Image

Figure 2 (Figure 5 Figure2)

Figure 2 (Figure 5 Figure2)
A line graph displaying mean plasma concentration of R-Oxybutynin (ng/mL) over time (hours). The graph shows concentration peaking around 1 hour, then gradually decreasing over a 12-hour period with error bars indicating variability at each time point.*
FDA Label Image

Table 3 (Figure 6 Table3)

Table 3 (Figure 6 Table3)
A data table listing adverse events by body system for Oxybutynin Chloride (5-20 mg/day, n=199). It categorizes adverse events such as urinary tract infection, insomnia, dizziness, blurred vision, dry mouth, constipation, and urinary hesitancy with corresponding percentages of occurrence.*
FDA Label Image
Kvk Logo (Figure 7 Company Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.